Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema (IBV®Valve)

A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

This trial is for men and women between the ages of 40 and 74 who have a confirmed diagnosis of emphysema. The objective of the trial is to determine the safety and effectiveness of the IBV Valve at redirecting airflow from diseased portions of the lung to healthier areas to achieve improvement in disease-related health status.

Study Overview

• Status: Completed
• Conditions: Emphysema; COPD
• Intervention / Treatment: Device: IBV® Valve System

Detailed Description

The IBV Valve Trial is a multi-center clinical trial evaluating the IBV Valve System, a non-surgical treatment for patients with emphysema. The IBV Valve System does not require traditional surgery or surgical incisions. The valves are placed during a bronchoscopic procedure. The IBV Valve System is designed to redirect airflow from diseased portions of the lung to healthier areas to achieve improvement in disease-related health status. Although the valves are intended to be permanent, they are designed to be removed if necessary.

The IBV Valve Trial is a randomized, blinded trial. This means that participants are divided into two groups but do not know to which group they have been assigned.

The IBV Valve Treatment Group receives valves, and the Control Group does not. A random selection process decides the group assignments (participants will not be able to choose their group). In the trial, everyone will have a 50 percent chance (similar to a coin toss) to be assigned to one group or the other.

All Participants in this Clinical Trial will:

Receive a diagnostic bronchoscopy that will allow an expert in lung health to evaluate their lungs.

Be under the care of a highly qualified lung doctor for the entire time they are in the trial, regardless of whether they are in the Treatment Group or the Control Group.

Receive regular periodic check-ups and health assessments throughout the 6 month trial period.

The procedure, all testing, and doctor visits are provided at no cost to participants of both the IBV Valve Treatment Group and the Control Group.

At the completion of their 6-month visit, participants will be told if they were assigned to the Treatment Group or the Control Group. If participants were assigned to the group that did not receive valves (the Control Group), they will be given the option to be re-evaluated by the clinical trial doctor, to determine if they can have valve treatment.

• Study Type: Interventional
• Enrollment (Actual): 277
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama at Birmingham
  • California
    • Los Angeles, California, United States, 90095
      • University of California Los Angeles (UCLA)
    • Los Angeles, California, United States, 90027
      • Kaiser Permanente Medical Center
    • Mission Viejo, California, United States, 92691
      • Mission Internal Medicine Group
    • Sacramento, California, United States, 95817
      • University of California Davis Medical Center
    • San Diego, California, United States, 92103
      • University of California San Diego
  • Colorado
    • Denver, Colorado, United States, 80206
      • National Jewish Medical & Research Center
  • Florida
    • Gainesville, Florida, United States, 32610
      • University of Florida
    • Sarasota, Florida, United States, 34239
      • Sarasota Memorial Hospital
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory Healthcare
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago
    • Elk Grove Village, Illinois, United States, 60007
      • Alexian Brothers Hospital Network
    • Springfield, Illinois, United States, 62794
      • Southern Illinois University School of Medicine
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa Hospitals and Clinics
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • University of Louisville
  • Maryland
    • Baltimore, Maryland, United States, 21237
      • Pulmonary and Critical Care Associates of Baltimore
  • Minnesota
    • Saint Paul, Minnesota, United States, 55101
      • Health Partners Research Foundation/Regions Hospital
  • New Jersey
    • Summit, New Jersey, United States, 07901
      • Pulmonary and Allergy Associates
  • New York
    • New York, New York, United States, 10032
      • Columbia University Medical Center
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine
  • Ohio
    • Akron, Ohio, United States, 44307
      • Akron General Medical Center
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Foundation
  • Oklahoma
    • Tulsa, Oklahoma, United States, 74127
      • Oklahoma State University
  • Oregon
    • Portland, Oregon, United States, 97227
      • Kaiser Permanente Northwest
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18103
      • Lehigh Valley Hospital
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania
  • Rhode Island
    • Providence, Rhode Island, United States, 02903
      • Rhode Island Hospital
  • Texas
    • San Antonio, Texas, United States, 78258
      • University of Texas Health Science Center
    • Temple, Texas, United States, 76508
      • Scott and White Memorial Hospital
  • Utah
    • Salt Lake City, Utah, United States, 84148
      • University of Utah
  • Virginia
    • Charlottesville, Virginia, United States, 22908
      • University of Virginia Health System
  • Washington
    • Seattle, Washington, United States, 98195
      • University of Washington
    • Tacoma, Washington, United States, 98405
      • Franciscan Research Center
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College Of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 74 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Candidates have mostly upper lobe, severe emphysema.
• Must be able to participate in standard exercise testing.
• Willing to abstain from cigarette smoking for 4 months prior and during the entire trial.
• Willing to participate in a randomized, blinded study and complete the required follow-up visits during the study period.
• Willing to participate in multiple visits to a medical center for health assessment tests.
• Willing to have a minimum of one overnight stay in the hospital.

Exclusion Criteria:

• Evidence of another co-existing major medical disease.
• Unable to tolerate, flexible bronchoscopy procedures.
• Active asthma, chronic bronchitis.
• Diffuse emphysema pattern, alpha 1-antitrypsin deficiency.
• Has had prior lung volume reduction surgery.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 1; The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision	Device: IBV® Valve System; The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
SHAM_COMPARATOR: 2; The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.	Device: IBV® Valve System; The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Difference between responder rates of the treatment & control groups, responders defined as subjects with clinically meaningful improvements in disease-related health status (SGRQ) & regional lung volume changes as measured by quantitative CT scan.	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
The difference between average 6 minute walk test results for treatment & control groups.	6 months

Collaborators and Investigators

• Sponsor: Spiration, Inc.

Publications and helpful links

General Publications

• Wood DE, Nader DA, Springmeyer SC, Elstad MR, Coxson HO, Chan A, Rai NS, Mularski RA, Cooper CB, Wise RA, Jones PW, Mehta AC, Gonzalez X, Sterman DH; IBV Valve Trial Research Team. The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol. 2014 Oct;21(4):288-97. doi: 10.1097/LBR.0000000000000110.

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 1, 2007
• Primary Completion (ACTUAL): February 1, 2011
• Study Completion (ACTUAL): August 1, 2017

Study Registration Dates

• First Submitted: May 16, 2007
• First Submitted That Met QC Criteria: May 16, 2007
• First Posted (ESTIMATE): May 17, 2007

Study Record Updates

• Last Update Posted (ACTUAL): April 17, 2018
• Last Update Submitted That Met QC Criteria: April 16, 2018
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Keywords: COPD; Emphysema; Shortness of Breath; IBV® Valve; Spiration
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Emphysema
• Other Study ID Numbers: CPR-01377